Taysha Gene Therapies (TSHA) Misses Q3 EPS by 1c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q3 EPS of ($0.10), $0.01 worse than the analyst estimate of ($0.09). Revenue for the quarter came in at $1.79 million versus the consensus estimate of $1.74 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
• Fed policy stance keeps Treasury yields high, says Citadel Securities
• Canadian trade officials to meet U.S. counterparts in Washington Monday